Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MNOV – Medicinova Inc

Float Short %

0.32

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.05

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

1.23

Target Price

7

Analyst Recom

1

Performance Q

-10.87

Relative Volume

0.47

Beta

0.44

Ticker: MNOV




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15MNOV1.330.010.00223
2025-08-18MNOV1.3150.010.00258
2025-08-19MNOV1.3050.010.00335
2025-08-20MNOV1.320.010.00335
2025-08-21MNOV1.30.010.00335
2025-08-22MNOV1.320.010.00335
2025-08-25MNOV1.310.010.00356
2025-08-26MNOV1.360.010.00356
2025-08-27MNOV1.390.010.00355
2025-08-28MNOV1.350.010.00355
2025-08-29MNOV1.3150.010.00355
2025-09-02MNOV1.30820.010.00355
2025-09-03MNOV1.320.010.00355
2025-09-04MNOV1.3442N/AN/A0
2025-09-05MNOV1.3N/AN/A0
2025-09-08MNOV1.270.000.00407
2025-09-09MNOV1.280.000.00407
2025-09-10MNOV1.280.000.00407
2025-09-11MNOV1.2650.000.00408
2025-09-12MNOV1.250.000.00408
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15MNOV1.33- - -0.50
2025-08-18MNOV1.31- - -0.50
2025-08-19MNOV1.30- - -0.50
2025-08-20MNOV1.32- - -0.50
2025-08-21MNOV1.30- - -0.50
2025-08-22MNOV1.33- - -0.50
2025-08-25MNOV1.31- - -0.50
2025-08-26MNOV1.36- - -0.50
2025-08-28MNOV1.34- - -0.50
2025-08-29MNOV1.32- - -0.50
2025-09-02MNOV1.30- - -0.50
2025-09-03MNOV1.32- - -0.50
2025-09-04MNOV1.35- - -0.50
2025-09-05MNOV1.29- - -0.50
2025-09-08MNOV1.26- - -0.50
2025-09-09MNOV1.28- - -0.50
2025-09-10MNOV1.28- - -0.50
2025-09-11MNOV1.25- - -0.50
2025-09-12MNOV1.23- - -0.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15MNOV0.00-0.550.26
2025-08-18MNOV0.00-1.480.26
2025-08-19MNOV0.00-1.480.26
2025-08-20MNOV0.00-1.480.26
2025-08-21MNOV0.00-1.480.26
2025-08-22MNOV0.00-1.480.26
2025-08-25MNOV0.00-0.610.26
2025-08-26MNOV0.00-0.610.26
2025-08-27MNOV0.00-0.610.27
2025-08-28MNOV0.00-0.610.27
2025-08-29MNOV0.00-0.610.27
2025-09-02MNOV0.00-0.600.27
2025-09-03MNOV0.00-0.600.27
2025-09-04MNOV0.00-0.600.27
2025-09-05MNOV0.00-0.600.27
2025-09-08MNOV0.00-0.600.27
2025-09-09MNOV0.00-0.600.27
2025-09-10MNOV0.00-0.600.27
2025-09-11MNOV0.00-0.600.32
2025-09-12MNOV0.00-0.600.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

-0.6

Beta

0.44

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

22

Growth Score

24

Sentiment Score

4

Actual DrawDown %

88.6

Max Drawdown 5-Year %

-87.1

Target Price

7

P/E

Forward P/E

PEG

P/S

464.07

P/B

1.29

P/Free Cash Flow

EPS

-0.24

Average EPS Est. Cur. Y​

-0.5

EPS Next Y. (Est.)

-0.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8775.8

Relative Volume

0.47

Return on Equity vs Sector %

-50.1

Return on Equity vs Industry %

-36.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

MediciNova, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading